Latest 30 News in the Life Sciences Industry

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress

By: PR Newswire Association LLC. - 22 Jun 2025

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

By: PR Newswire Association LLC. - 22 Jun 2025

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

By: PR Newswire Association LLC. - 22 Jun 2025

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

By: GlobeNewswire - 22 Jun 2025

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

By: PR Newswire Association LLC. - 22 Jun 2025

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

By: GlobeNewswire - 22 Jun 2025

Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions

By: PR Newswire Association LLC. - 22 Jun 2025

Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research

By: PR Newswire Association LLC. - 22 Jun 2025

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

By: GlobeNewswire - 22 Jun 2025

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

By: PR Newswire Association LLC. - 22 Jun 2025

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

By: PR Newswire Association LLC. - 22 Jun 2025

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

By: PR Newswire Association LLC. - 22 Jun 2025

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

By: PR Newswire Association LLC. - 22 Jun 2025

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

By: PR Newswire Association LLC. - 21 Jun 2025

Local Dentist (Smiles By The Sea Family Dentistry) Joins National Effort to Support Veterans This Fourth of July

By: PR Newswire Association LLC. - 21 Jun 2025

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

By: GlobeNewswire - 21 Jun 2025

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

By: PR Newswire Association LLC. - 21 Jun 2025

MolecuLight Showcases Innovative Multimodal Imaging with Thermal Capabilities at St. Louis Wound & Vascular Symposium

By: PR Newswire Association LLC. - 21 Jun 2025

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

By: PR Newswire Association LLC. - 21 Jun 2025

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

By: GlobeNewswire - 21 Jun 2025

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

By: GlobeNewswire - 21 Jun 2025

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

By: GlobeNewswire - 21 Jun 2025

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

By: GlobeNewswire - 20 Jun 2025

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

By: GlobeNewswire - 20 Jun 2025

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

By: GlobeNewswire - 20 Jun 2025

The Ensign Group, Inc. Announces Retirement of Its Executive Chairman

By: GlobeNewswire - 20 Jun 2025

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

By: GlobeNewswire - 20 Jun 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

By: GlobeNewswire - 20 Jun 2025

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By: GlobeNewswire - 20 Jun 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

By: GlobeNewswire - 20 Jun 2025

Looking for more life science news?

Browse Biotechgate for global news, company information, product pipelines, licensing opportunities, management details and much more.

Partners

Upcoming Life Sciences Events

July 2025
- ON Helix 2025
August 2025
- Biotechgate Digital Partnering August 2025
September 2025
- Boston: LSX USA Congress

See Events »

Add an Event »

Latest company news

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
22 Jun 2025 (PR Newswire Association LLC.)

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes
22 Jun 2025 (PR Newswire Association LLC.)

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes
22 Jun 2025 (PR Newswire Association LLC.)